ArticleHypertension research : official journal of the Japanese Society of Hypertension2025
Increased plasma levels of erythropoietin after renal denervation in patients with resistant hypertension.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Lung-Kidney Axis: A Coordinated Regulation of Oxygen Sensing and Erythropoiesis.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin (Epo) plays a crucial role in the formation and maturation of erythrocytes and is produced primarily by peritubular cells in the renal cortex. Previous studies suggest that renal sympathetic nerve activity (RSNA) may influence Epo regulation. Catheter-based renal denervation (RDN) has been shown to reduce renal noradrenaline spillover and blood pressure in patients with resistant hypertension. We therefore aimed to investigate whether RDN influences Epo levels. 33 patients with resistant hypertension (age 61 ± 12 y; baseline office blood pressure (BP) 165 ± 16/85 ± 18 mmHg despite treatment with an average of 4.9 ± 1.7 antihypertensive medications) underwent bilateral RDN. Plasma levels of Epo, office blood pressure, 24 h ambulatory blood pressure monitoring (ABPM), muscle sympathetic nerve activity (MSNA), renal function and haemoglobin were measured before the procedure and at 3 months follow-up. Antihypertensive medication was not changed during the first 3 months after RDN. Office blood pressure was reduced by 15 ± 19/5 ± 12 mmHg at 3 months after denervation (p < 0.001 for systolic BP; p = 0.033 for diastolic BP). 24h-mean systolic and diastolic BP were also reduced (from 145 ± 16 to 140 ± 18 mmHg; p = 0.036, and from 80 ± 11 to 77 ± 12 mmHg; p = 0.024), respectively. While haemoglobin levels remained unchanged, a significant increase in plasma Epo levels was observed at 3 months after RDN (7.81 ± 3.68 versus 9.88 ± 5.06 mIU/mL; p = 0.025). Changes in Epo levels correlated with baseline MSNA (r = 0.580, p = 0.004 for burst frequency; r = 0.471, p = 0.023 for burst incidence), such that the increase in Epo was most pronounced in patients with high baseline MSNA. The RDN-induced changes in MSNA tended to correlate inversely with changes in Epo levels (r = -0.402; p = 0.064). Our findings suggest that RDN is associated with increased plasma levels of Epo in the absence of changes in haemoglobin, and that these effects are possibly mediated via a reduction in sympathetic nerve activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.